STAAR Surgical Company (STAA)

Market Cap	2.29B
Revenue (ttm)	322.42M
Net Income (ttm)	21.35M
Shares Out	48.87M
EPS (ttm)	0.43
PE Ratio	108.72
Forward PE	80.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	365,003
Open	46.57
Previous Close	46.34
Day's Range	45.51 - 47.30
52-Week Range	26.66 - 73.13
Beta	0.88
Analysts	Buy
Price Target	46.00 (-1.69%)
Earnings Date	May 1, 2024

About STAA

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are prima...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1982
• Employees: 1,115
• Stock Exchange: NASDAQ
• Ticker Symbol: STAA

Financial Performance

In 2023, STAA's revenue was $322.42 million, an increase of 13.37% compared to the previous year's $284.39 million. Earnings were $21.35 million, a decrease of -46.18%.

Analyst Forecast

According to 10 analysts, the average rating for STAA stock is "Buy." The 12-month stock price forecast is $46.0, which is a decrease of -1.69% from the latest price.

Price Target

$46.0

(-1.69% downside)

Analyst Consensus: Buy